Company intelligence / Profile preview

Proteon Pharmaceuticals

Ownership: Private
Development stage: Commercial

Overview

Products are registered and commercially available in selected markets throughout Southeast Asia, South America, and Africa. EFSA has confirmed BAFASAL®'s efficacy in poultry production, and BAFASAL PRO has been registered in Brazil.

Therapeutic areas: Infectious Diseases
Modalities: Bacteriophage-based solutions
Industry: Veterinary

Drug pipeline

3 assets

BAFASAL

Commercial

Indications: Salmonella control in poultry

2 more assets in the full pipeline.

Request access →

Partnerships

Nutreco

Beyond the preview

Go deeper on Proteon Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Proteon Pharmaceuticals.

Explore the full profile